Wang Shang, Yang Lijuan, Wang Lian, Gao Ling, Xu Biao, Xiong Yunyun
Department of Cardiology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China (S.W., L.W., L.G., B.X.).
Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China (L.Y.).
J Am Heart Assoc. 2015 May 19;4(5):e001681. doi: 10.1161/JAHA.114.001681.
Recent studies have reported conflicting results on the association between selective serotonin reuptake inhibitors (SSRIs) and the risk of heart defects. We aimed to assess the association between SSRIs in pregnant women during the first trimester and the risk of congenital heart defects.
PubMed and EMBASE up to July 2014 were searched for population-based cohort studies that reported SSRIs in pregnant women during the first trimester and live infants' heart defects at follow-up. A meta-analysis of published data was undertaken primarily by means of fixed-effects models. Four cohort studies including 1 996 519 participants were included with a mean follow-up period ranging from discharge to 72 months. SSRIs were not associated with increased risks of heart defects 1.06 (95% confidence interval: 0.94 to 1.18).
SSRIs during the first trimester in pregnant women were not associated with increased risks for newborn heart defects.
近期研究报告了选择性5-羟色胺再摄取抑制剂（SSRI）与心脏缺陷风险之间的关联存在相互矛盾的结果。我们旨在评估孕早期孕妇使用SSRI与先天性心脏缺陷风险之间的关联。
检索截至2014年7月的PubMed和EMBASE数据库，查找基于人群的队列研究，这些研究报告了孕早期孕妇使用SSRI以及随访时活产婴儿的心脏缺陷情况。主要通过固定效应模型对已发表数据进行荟萃分析。纳入了四项队列研究，共1996519名参与者，平均随访期从出院至72个月。SSRI与心脏缺陷风险增加无关，比值比为1.06（95%置信区间：0.94至1.18）。
孕早期孕妇使用SSRI与新生儿心脏缺陷风险增加无关。
